StemCell Therapy

As Biotechnology businesses, Trillium Therapeutics Inc. (NASDAQ:TRIL) and Cidara Therapeutics Inc. (NASDAQ:CDTX), are affected by compare. This especially applies to their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Valuation and Earnings

In table 1 we can see Trillium Therapeutics Inc. and Cidara Therapeutics Inc.s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 has Trillium Therapeutics Inc. and Cidara Therapeutics Inc.s net margins, return on equity and return on assets.

Institutional & Insider Ownership

Institutional investors held 40.67% of Trillium Therapeutics Inc. shares and 69.6% of Cidara Therapeutics Inc. shares. Insiders held 0.26% of Trillium Therapeutics Inc. shares. Insiders Comparatively, held 1.5% of Cidara Therapeutics Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Trillium Therapeutics Inc.s stock price has bigger decline than Cidara Therapeutics Inc.

Summary

On 6 of the 9 factors Trillium Therapeutics Inc. beats Cidara Therapeutics Inc.

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companys lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.

Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of various diseases. Its lead product candidate is CD101 IV, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious, invasive fungal infections. The company also develops CD201, a novel bispecific antimicrobial immunotherapy for the treatment of multidrug-resistant gram-negative bacterial infections, including those caused by pathogens harboring the mcr-1 plasmid. In addition, it develops a proprietary immunotherapy technology platform Cloudbreak, which is designed to create compounds that direct immune system to attack and eliminate bacterial, fungal or viral pathogens. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

See more here:
Comparing of Trillium Therapeutics Inc. (TRIL) and Cidara Therapeutics Inc. (NASDAQ:CDTX) - MS Wkly

This entry was posted on October 18, 2019 at 3:40 am and is filed under Stem Cell Negative. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |